June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
HER2 expression in retinoblastoma: a potential therapeutic target?
Author Affiliations & Notes
  • David Cordeiro Sousa
    Ophthalmology, Hospital de Santa Maria, Lisboa, Portugal
    Centro de Estudos Ciências da Visão, Universidade de Lisboa, Lisboa, Portugal
  • Pablo Zoroquiain
    McGill University Ocular Pathology Laboratory, MUHC, Montreal, Quebec, Canada
  • Evangelina Esposito
    McGill University Ocular Pathology Laboratory, MUHC, Montreal, Quebec, Canada
  • Maria Eugenia Orellana
    Instituto Anatomopatológico 'Dr. José A. O'Daly', Universidad Central de Venezuela, Caracas, Venezuela, Bolivarian Republic of
  • Bruna Duarte Moron de Andrade
    McGill University Ocular Pathology Laboratory, MUHC, Montreal, Quebec, Canada
  • Miguel N Burnier
    McGill University Ocular Pathology Laboratory, MUHC, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   David Sousa, None; Pablo Zoroquiain, None; Evangelina Esposito, None; Maria Orellana, None; Bruna Duarte Moron de Andrade, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1776. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Cordeiro Sousa, Pablo Zoroquiain, Evangelina Esposito, Maria Eugenia Orellana, Bruna Duarte Moron de Andrade, Miguel N Burnier; HER2 expression in retinoblastoma: a potential therapeutic target?. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1776.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinoblastoma (RB) is the most common primary intraocular malignancy in children. Current therapies are associated with both high short- and long-term morbidity. Human epidermal growth factor receptor 2 (HER2) is a transmembrane protein detected in 15%–30% of breast cancers, which has also been described in other malignancies. Recently, it was reported that a truncated version of this protein is expressed in RB, which is responsive to targeted therapies in vitro. Herein, we scored HER2 expression in RB samples and discuss its potential clinical utility.

Methods : A total of 60 RB cases and the Y79 RB cell line were evaluated for HER2 expression using a monoclonal antibody and the fully automated Ventana immunostaining system. HER2 expression was evaluated using the traditional 0 to 3+ scoring method according to the membranous staining pattern in archival formalin-fixed, paraffin-embedded RBs. A cell block was generated with the Y79 cell line, and it was scored in a similar fashion.

Results : The mean age at enucleation was 31.6 ± 31.5 months, while the mean time from diagnosis to enucleation was 11.8 ± 11.2 months (range 1–44 months). Five cases (8%) were multifocal. HER2 expression was negative in all RB cases (49 cases scored 0 and 11 scored 1+) and in the Y79 cell line.

Conclusions : Despite the large sample size, and the inclusion of a RB cell line, in our study, there was no significant expression of HER2 in RB. Based on our results, it is unlikely that anti-HER2 therapies will be effective for treating RB via the traditional pathways.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×